Strain AI (SAI001)

Strain AI (SAI001) is a Class II medical device software designed for noninvasive post-processing of cardiac ultrasound images to accurately measure global longitudinal strain (GLS) in adults with suspected heart disease. Its methodology involves advanced image analysis algorithms that integrate with existing ultrasound systems, validated through comprehensive testing to ensure reliability and substantial equivalence to legally marketed products.

On November 20, 2024, a regulatory body informed Exo Inc. that its device, Strain AI (SAI001), has been determined to be substantially equivalent for its stated indications for use. This classification allows the device, a Class II medical image management and processing system, to be marketed.The Strain AI (SAI001) is a software designed to noninvasively process cardiac ultrasound images, providing measurements of global longitudinal strain (GLS) in adult patients with suspected disease. This software functions as a post-processing tool that integrates with existing ultrasound imaging devices, analyzing images after acquisition to provide quantitative GLS measurements. Its safety and performance were evaluated through comprehensive software verification and validation testing, including clinical performance assessments across diverse patient demographics. The evaluations confirmed the device's accuracy and reliability, concluding that it shares the same intended use, design, principles of operation, technological characteristics, and safety features as a comparable legally marketed product.

AI Regulatory Concerns

Powered by

Jev reads the full FDA letter and returns calibrated concern probabilities per regulatory category. These are AI estimates, not regulatory advice.

• Q1. What specific clinical endpoints or outcomes were used to validate the accuracy and reliability of Strain AI (SAI001) in comparison to the predicate device?; How does the Strain AI (SAI001) algorithm handle image quality variations or artifacts that are common in real-world cardiac ultrasound images?; What is the inter-observer and intra-observer variability of GLS measurements obtained using Strain AI (SAI001) compared to manual or other automated methods?; Can Strain AI (SAI001) be integrated with PACS systems or electronic health records to streamline data flow and clinical decision-making?; Are there any specific types of suspected cardiac diseases or patient demographics for which Strain AI (SAI001)'s performance has shown particular strengths or limitations?